Research into supplementation with sodium phosphate has not investigated the effects of a repeated supplementation phase. Therefore, this study examined the potential additive effects of repeated sodium phosphate (SP) supplementation on cycling time-trial performance and peak oxygen uptake (VO 2peak ). Trained male cyclists (N = 9, M ± SD VO 2peak = 65.2 ± 4.8 ml · kg -1 · min -1 ) completed baseline 1,000-kJ time-trial and VO 2peak tests separated by 48 hr, then ingested either 50 mg · kg fat-free mass -1 · d -1 of tribasic SP or a combined glucose and NaCl placebo for 6 d before performing these tests again. A 14-d washout period separated the end of one loading phase and the start of the next, with 2 SP and 1 placebo phase completed in a counterbalanced order. Although time-trial performance (55.3-56.5 min) was shorter in SP1 and SP2 (~60-70 s), effect sizes and smallest-worthwhile-change values did not differ in comparison with baseline and placebo. However, mean power output was greater than placebo during time-trial performance at the 250-kJ and 500-kJ time points (p < .05) after the second SP phase. Furthermore, mean VO 2peak values (p < .01) were greater after the SP1 (3.5-4.3%), with further improvements (p < .01) found in SP2 (7.1-7.7%), compared with baseline and placebo. In summary, repeated SP supplementation, ingested either 15 or 35 d after initial loading, can have an additive effect on VO 2peak and possibly time-trial performance.
Considerable research has focused on legal and medically safe nutritional supplements (with minimal or no negative side effects) that may lead to improved exercise performance. One such supplement is phosphate, which may improve endurance-exercise performance and peak aerobic capacity (VO 2peak ; Folland, Stern, & Brickley, 2008; Kreider et al., 1992; Kreider, Miller, Williams, Somma, & Nasser, 1990) . Phosphate is an essential mineral that must be obtained from the diet, with sources including red meat, fish, poultry, milk products, eggs, cereal, and vegetables (Lee, Brautbar, & Kleeman, 1981; Stoff, 1982) . It is integral in many structural components of the body, including skeletal bone (Silverberg, Shane, & Clemens, 1986; Takeda et al., 2000) , cell membranes and intracellular organelles (in the form of phospholipids), and as constituents of highly active intracellular compounds in DNA and RNA (Berner & Shike, 1988) . Phosphates are integral in the human energy-production cycles, forming the basic structural components phosphocreatine and ATP, important components in oxygen transport within the red blood cell, including 2,3-diphosphoglycerate (DPG) and lactic-acid-buffering components (phosphate buffer).
Based on these roles of phosphate in the body, many studies have examined the effects of various doses and timing of phosphate supplementation (in the form of sodium phosphate; SP) in an attempt to enhance exercise performance. Supplementation with SP typically involves ingestion of 3-4 g/day, split into four equal doses, for a period of 3-6 days (Cade et al., 1984; Folland et al., 2008; Kreider et al., 1992; Kreider et al., 1990; Wallace et al., 1997) . Such doses have been reported to result in improvements in VO 2peak (Cade et al., 1984; Kreider et al., 1992; Wallace et al., 1997) and endurance performance (Kreider et al., 1992) , although not all studies have observed ergogenic benefits after SP supplementation (Brennan & Connolly, 2001 ; Thompson et al., 1990; Weatherwax et al., 1986; West, Ayton, Wallman, & Guelfi, 2012) . Nonetheless, multiple mechanisms for performance improvements after SP loading have been suggested, including increased 2,3-DPG concentrations, leading to a greater unloading of oxygen from hemoglobin to the muscle (Cade et al. 1984; Chanutin & Curnish, 1967; Farber et al., 1987) ; increased extracellular phosphate availability, resulting in greater intracellular diffusion and enhanced oxidative metabolism (Lichtman, Miller, Cohen, & Waterhouse, 1971; Thompson et al., 1990) ; increased anaerobic glycolysis, phosphocreatine synthesis, and ATP production (Brain & Card, 1972; Chanutin and Curnish, 1967; Lichtman & Miller, 1970) ; increased cardiac muscle contractility (Czuba, Zajac, Poprzecki, & Cholewa, 2009; Czuba, Zajac, Poprzecki, Cholewa, & Woska, 2008; Kreider et al., 1992) ; and increased buffering capacity (Avioli, 1988) . With so many potential mechanisms by which phosphate loading may influence metabolism, it has yet to be conclusively determined to what extent phosphate loading may benefit exercise performance. Furthermore, no studies have trialed repeated loading phases, and it is possible that additive effects could result from this supplementation regimen, based on improvements seen by Czuba et al. (2009) , who found increased power output after an extended period of loading (21 days) after an initial 6-day loading period. Therefore, the purpose of this study was to determine whether a second phase of 6 days of SP ingestion might have an additive effect on endurance-exercise performance and VO 2peak .
Methods

Participants
Twelve competitive male cyclists volunteered for this study, although 3 failed to complete all testing phases due to injury. The remaining 9 participants (M ± SD VO 2peak 65.2 ± 4.8 ml · kg -1 · min -1 , years of competitive cycling 6.9 ± 3.8, age 32.6 ± 7.4 years, body mass 77.8 ± 9.8 kg, height 179.0 ± 7.1 cm, body fat 13.4% ± 5.8%, fat-free mass [FFM] 67.8 ± 6.0 kg) were not taking any nutritional supplements for at least 2 months before or during this study. The human research ethics committee of the University of Western Australia approved the study, and all participants provided written informed consent. The study was conducted during the Western Australia competitive cycling season, with each participant required to maintain a consistent training volume. This meant that each participant trained for a mean (± SD) of 300 ± 97 km/week, with an additional 6.6 ± 6.0 hr of cross-training in other physical activities.
Experimental Design
Participants refrained from exercise for 24 hr before each experimental session, with exercise testing taking place at the same time of day to control for circadian variation. A placebo, counterbalanced, double-blind crossover study was conducted over a 2-month period. In an initial habituation trial, medical and training questionnaires were completed, anthropometric measurements were recorded, and body composition (FFM) was assessed using a dual-energy X-ray absorptiometry scan (Lunar Prodigy, encore 2004, GE Medical Systems, Madison, WI) . Participants then completed the initial stages of a graded exercise test (first three incremental intensities of exercise while breathing through a mouthpiece), and then 5 min later a 1,000-kJ cycling time trial, to accustom themselves with the tests and procedures to be used during the subsequent experimental trials. All exercise testing was performed on an air-braked cycle ergometer (Evolution bicycles, Geelong, Australia) linked to a customized computer program for the determination of power output (Cyclemax version 6.3, School of Sport Science, Exercise and Health, University of Western Australia). This ergometer has fan blades attached to the flywheel that displace air as the wheel turns, making resistance proportional to pedaling rate. This reflects the type of resistance encountered during real road cycling. This setup was intended to maximize ecological validity by replicating the variation in pedal rate and gearing experienced during a real cycling time trial on the road. The cycling ergometer had six gears that participants were able to adjust, enabling individual resistance and cadence to be set.
Participants then completed four separate phases of testing, including a baseline trial, a placebo supplementation trial, and two SP supplementation trials (SP1, SP2) in a double-blind, counterbalanced order. For the supplementation trials, participants completed 6 days of loading with either placebo or SP, with the 1,000-kJ cycling time trial performed on the seventh day, followed 48 hr later by a graded exercise test to exhaustion. A 14-day washout period beginning the day after supplementation then followed, before loading was commenced for the next phase of supplementation and testing.
Supplementation
Participants were given either tribasic SP dodecahydrate (Challenge Chemicals Australia, Kwinana, Western Australia, 50 mg · kg FFM -1 · day -1 ) or a placebo mix equivalent of glucose and table salt (ratio 9:1). The placebo included salt to mask the taste of the supplement ingested, as SP has a slightly salty taste. Both supplements were ground into a fine powder to make them indistinguishable from each other. This daily amount was divided into four equal doses and ingested with meals over the course of each day (4-to 5-hr interval) in opaque capsules (Melbourne Food Depot, East Brunswick, Victoria Australia) for a 6-day period until 8 hr before the scheduled exercise test. Each capsule dose was emptied into a glass and consumed with 15 g of Powerade powder (Coca-Cola Amatil, Australia) that had been dissolved in ~300 ml of water. This procedure was followed to prevent gastrointestinal upset (experienced in prior pilot testing with SP and reported by West et al., 2012) and to mask the taste. Participants consumed their normal diet during the supplementation period.
1,000-kJ Time Trial
Previous research has used 500 kJ to approximate a distance of 20 km (Peeling, Bishop, & Landers, 2005) , so the target total exercise amount of 1,000 kJ was chosen to represent approximately 40 km, similar to the protocol of Ihsan, Landers, Brearley, and Peeling (2010) . When performing the 1,000-kJ time trial, participants cycled in an isolated room with no outside influences. A computer screen allowed them to see the amount of kJ left to complete (which counted down from 1,000 kJ) but kept them blinded to their power output and duration of performance. Blood samples (35 μl) for lactate determination using a blood-gas analyzer (ABL 725, Radiometer, Copenhagen, Denmark) were collected from the earlobe at rest and immediately postexercise. Heart rate was measured (Polar Electro Oy Professorintie, Kempele, Finland) every 250 kJ during the time trial.
VO 2peak Protocol
VO 2peak was assessed using a graded exercise test consisting of incremental stages of cycling starting at 150 W and increasing by 50 W every 3 min, with 1 min of rest between stages to allow for capillary blood to be sampled for lactate determination. The test was terminated when the participant could no longer maintain the required intensity of exercise. Measures of heart rate were made 30 s before the end of each 3-min exercise interval. During this test, participants breathed through a mouthpiece connected to a computerized gas-analysis system consisting of a ventilometer (Universal ventilation meter, VacuMed, Ventura, CA), which was calibrated before the test using a 1-L syringe. Expired oxygen and carbon dioxide concentrations were analyzed using Ametek gas analyzers (Applied Electrochemistry, SOV S-3A11 and COV CD-3A, Pittsburgh, PA), which were calibrated immediately before and verified after each test using a certified beta-grade gravimetric gas mixture of known concentration (BOC Gases, Chatswood, Australia). Both the ventilometer and gas analyzers were connected to a computer that measured and displayed variables every 15 s. Each participant's VO 2peak was calculated using the sum of the four highest consecutive 15-s VO 2 values recorded during the test. Heart rate, blood lactate concentration, VO 2 , and power output at each individual's anaerobic threshold were determined using the modified D max method.
Determination of Serum Phosphate
Before the baseline time trial and after each supplementation phase, a venous blood sample was taken from an antecubital vein into a BD Vacutainer SST II Advance. These were left to clot at room temperature for 60 min before being centrifuged at 1,000 g at 4 °C for 15 min. The serum obtained was stored at -80 °C for later analysis, with serum phosphate determined using an Abbott Architect c16000 analyzer, using the specified Abbott reagents (Abbott Laboratories, Abbott Park, IL). Observed coefficients of variation were 4.2% at a level of 0.95 mmol/L and 2.0% at a level of 2.95 mmol/L.
Statistical Analysis
The effect of SP supplementation on time-trial performance and VO 2peak was analyzed by repeated-measures analysis of variance (ANOVA) with LSD post hoc comparisons (SPSS 18.0 for Windows). Significance was accepted when p ≤ .05. Cohen's d effect sizes (ES <.5, small; .5-.79, moderate; ≥.8, strong; Cohen, 1988) were also calculated to examine trends in the performance data. Further analysis identified the smallest worthwhile change (SWC) in performance scores between baseline, placebo, SP1, and SP2, using the method outlined by Batterham and Hopkins (2005) . The SWC was set at a Cohen's unit of .2, representing the hypothetically smallest change in physiological measures that would benefit the athlete. Where the chance of benefit or harm was calculated to be >5%, the true effect was deemed unclear. When clear interpretation was definitively possible, a qualitative descriptor was assigned to the following quantitative chances of benefit: 25-75%, benefit possible; 76-95%, benefit likely; 96-99%, benefit very likely; >99%, benefit almost certain (Batterham & Hopkins, 2005) . In addition, Pearson's correlation coefficients calculated the relationship between time-trial performance and VO 2peak and between change (Δ) in time-trial performance and Δ VO 2peak.
Results
1,000-kJ Cycling Time Trial
Seven of the nine participants completed successive SP trials, with the placebo trial coming before or after these. There was no effect of the order of administration of trials (p = .788), indicating that any improvements were not due to further habituation with the exercise protocol independent of the type of supplementation ingested. Compared with baseline, 7 of the 9 participants had a shorter time-trial time to completion in SP1, while 5 of the participants had a shorter time-trial time to completion in SP2. Despite SP1 and SP2 trials recording shorter time-trial times to completion than baseline and placebo trials, no differences, moderate effect sizes, or likely SWC probabilities were found (Tables 1A and 1B) . Similar results were evident in the split times recorded at 250, 500, 750, and 1,000-kJ time points, although mean power after SP2 was greater (p < .05) than placebo values at 250 and 500 kJ. Post-time-trial blood lactate values did not differ between trials, and heart-rate values were similar between trials, although SP2 recorded lower values than SP1 (750 kJ, p < .05) and baseline (1,000 kJ, p < .05), and SP1 recorded a higher value than placebo (750 kJ, p < .05).
VO 2peak
The effect of supplementation on VO 2peak is displayed in Tables 2A and 2B , which show the ANOVA results but not the SWC values (where relevant, these are included in the following text). Body mass measured before the VO 2peak test was not different between any of the trials. There was a main effect of supplementation (p, percentage change, ES, SWC: beneficial/ trivial/ harmful) on VO 2peak , with greater mean VO 2peak values after SP1 (both L/min and ml · kg -1 · min -1 ) than after placebo (p = .005, 3.4%, 0.55, 83/17/0). Similarly, after SP2 supplementation, a greater mean VO 2peak was also observed than at baseline (p = .005, 6.9%, .95, 99/1/0) and after placebo (p = .001, 7.1%, .97, 100/0/0). Furthermore,VO 2peak values for SP2 were greater than in SP1 (p = .049, 3.6%, .46, 88/12/1), suggesting that additional benefits were gained during the second supplementation phase. Despite these observed increases in VO 2peak , there was no effect of SP1 or SP2 on the mean power, VO 2 , or heart rate at which the anaerobic threshold occurred. Posttest blood lactate values were greater (p < .05) in SP1 than in the baseline and SP2 trials.
Shorter time-trial performance was associated with a higher VO 2peak (r = .823, p < .01 for pooled SP-trial values vs. baseline), but Δ in time-trial performance and Δ VO 2peak for SP1, SP2, and pooled values were not related (r = -.210 to .105, p > .05).
Serum Phosphate
Results did not differ between any of the supplementation phases for serum phosphate values (M ± SD baseline 1.33 ± 0.19, P 1.30 ± 0.14, SP1 1.34 ± 0.13, SP2 1.31 ± 0.21 mmol/L). Of note, in 13 of the 27 trials (48%), participants correctly identified that they were ingesting SP. None of the participants reported any episodes of gastrointestinal upset during SP supplementation.
Discussion
This is the first study to assess whether a second phase of SP supplementation might result in an additive effect on endurance performance and VO 2peak in well-trained male cyclists. While 1,000-kJ time-trial time to completion decreased (58-69 s) and power output increased (~5-7 W) after both SP trials, compared with placebo and baseline, the only significant results found were during the second SP phase for mean power at 250 kJ and 500 kJ compared with placebo. Furthermore, while a single phase of SP supplementation resulted in a greater mean Time to completion (min) 56.4 ± 6.9 56.5 ± 7.6 55.5 ± 6.8 55.3 ± 6.9 250 kJ 13.6 ± 1.8 13.5 ± 2.0 13.1 ± 1.8 13.1 ± 1.8 500 kJ 14.2 ± 1.8 14.4 ± 1.9 14.1 ± 1.6 13.9 ± 1.6 750 kJ 14.7 ± 1.8 14.8 ± 2.0 14.5 ± 1.7 14.3 ± 1.7 1,000 kJ 14.1 ± 1.8 13.9 ± 2.0 13.8 ± 1.9 14.0 ± 2. Results from previous studies assessing the effect of a single phase of SP supplementation on time-trial performance have been equivocal (Folland et al., 2008; Kreider et al., 1992; Kreider et al., 1990; Weatherwax et al., 1986) . Differences between results of these studies could relate to the mode of exercise used (cycling vs. running), the distance of the time trial (range of 8-40 km), and the length of the washout period (9-17 days). Notably, there was no conclusive benefit of SP1 on 1,000-kJ time-trial performance in the current study. Differences between the results of the current study and those of Kreider et al. (1992) , the only other study to assess the effects of SP on 40-km (or equivalent) cycle time-trial performance, could be due to the shorter washout period used in the current study (15 vs. 17 days), which may not have allowed for the complete elimination of SP, possibly benefiting subsequent placebo trials. For example, Cade et al. (1984) noted that it took approximately 2 weeks for red blood cell 2,3-DPG concentration to return to near baseline levels after 3 days of SP loading. Therefore, it is possible that a 6-day loading period, as used in the current study, may require a longer washout period to remove any carryover effects from phosphate supplementation. Another explanation for differences in results between studies may be the different SP dosing protocols used (50 mg · kg FFM -1 · day -1 , equating to ~3.4 g daily over 6 days in the current study, vs. 4 g/day over 3-4 days for Kreider et al., 1992) . It is possible that the larger daily dose used by Kreider et al. (1992) is needed for an ergogenic effect to occur in respect to endurance-exercise performance. Folland et al. (2008) also reported a benefit of 4 g/day of SP on 16.1-km cycle time-trial performance.
Improved aerobic capacity after SP1 and SP2 found in the current study is supported by the majority of studies that have assessed the effect of SP loading on VO 2max during a running or cycling protocol (Cade et al., 1984; Czuba et al., 2009; Kreider et al., 1992; Kreider et al., 1990; Stewart, McNaughton, Davies, & Tristam, 1990) . Specifically, Czuba et al. (2009) reported a greater mean-VO 2max and maximum expired ventilation, along with a lesser mean resting heart rate and maximal heart rate, in off-road cyclists after 6 days of loading with trisodium phosphate (50 mg · kg FFM -1 · day -1 ). Moreover, similar to the current study, those researchers reported that a further 21 days of SP supplementation (25 mg · kg FFM -1 · day -1 ) resulted in further improvement in these variables compared with baseline. In addition, maximum power (W) was greater and the ventilatory threshold shifted toward higher intensities of exercise (Czuba et al., 2009 ). Note. VO 2peak = peak oxygen consumption.
These changes were accompanied by greater mean values in serum concentrations of inorganic phosphate after both the 6-and 21-day loading protocols. Reasons proposed by the researchers to explain the ergogenic effects of SP after both the 6 and subsequent 21 days of loading were varied. First, the increase in V Emax seen immediately after the 6-day loading protocol, which continued to increase during the next 3 weeks of supplementation, was proposed by Czuba et al. (2009) to be a result of improved function of the diaphragm. This suggestion is supported by Aubier et al. (1985) , who reported a positive relationship (r = .73) between blood concentration of phosphates and transdiaphragmatic pressure. Furthermore, Aubier et al. noted that hypophosphatemia impaired the function of the diaphragm, with this suggesting that the reverse could apply with SP supplementation. Second, improved myocardial efficiency (i.e., increased stroke volume), as seen by decreased resting and maximal heart rate during the aerobic-capacity test, was also proposed by Czuba et al. (2009) to reflect the ergogenic effect of SP loading on exercise performance. Third, a tendency for an increase in erythrocyte 2,3-DPG concentration in the treatment group reported by these researchers raises the possibility of greater unloading of oxygen to the muscles and hence improved exercise performance. Notably, Czuba et al. (2009) reported a relationship between serum phosphate concentrations and the level of 2,3-DPG (r = .49, p = .01).
In addition, the greater mean serum phosphate concentrations reported after both supplementation phases supports the notion of a larger phosphate energy pool being available for energy consumption, which in turn may have played a role in improving aerobic capacity. Finally, a role for improved acid-base balance during intensive exercise due to enhanced buffering processes provided by SP supplementation was postulated by Czuba et al. (2009) but not confirmed by their results. All the factors described by Czuba et al. (2009) as having a role in improving exercise performance after SP supplementation may be applicable to exercise benefits seen in the current study, particularly after the SP2 trial. For example, evidence to support improved heart-rate function is demonstrated by all heart-rate values being lower during the 1,000-kJ time trial after SP2, compared with all other trials for every time point assessed (apart from placebo at 500 kJ), with this difference being less at the 750-kJ mark than with SP1 (154 ± 15 vs. 159 ± 12 beats/min) and at the 1,000-kJ mark than at baseline (163 ± 15 vs. 168 ± 11). Furthermore, blood lactate values after the 1,000-kJ time trial were lower (NS) after SP2 than with all other trials, despite a shorter completion time, suggesting a possible role for improved buffering capacity. Furthermore, while a lack of change in serum phosphate levels recorded between trials in the current study makes it difficult to assign an ergogenic effect to an increased phosphate pool being available for energy consumption, the relationship between serum phosphate concentration and improved exercise performance is unclear. For example, Kreider et al. (1992) found that resting serum phosphate levels did not differ between a phosphate and placebo trial yet reported improved aerobic capacity and time-trial performance after SP supplementation. Stewart et al. (1990) also reported an 11% increase in maximal oxygen uptake after SP supplementation, but without observable increases in resting or postexercise serum phosphate levels. Consequently, Kreider et al. (1992) suggested that serum phosphate concentrations may not accurately assess the effects of phosphate loading on intracellular phosphate levels and oxidative metabolism. Notably, serum phosphate levels after SP1 and SP2 in the current study were higher than those reported by Czuba et al. (2009; 1.34 and 1.31 mmol/L for SP1 and SP2 vs. 1.00 and 1.10 mmol/L after 6 and 21 days of SP loading, respectively), with Czuba et al. (2009) suggesting that the effectiveness of phosphate loading may depend on the initial concentration of serum phosphate in the blood. This premise may be particularly pertinent to endurance-exercise performance. Finally, while 2,3-DPG concentration was not assessed in the current study, greater mean VO 2peak values for SP1 and SP2, despite similar V Emax values for all trials, may suggest a role for greater oxygen extraction in the two SP trials, which may be indicative of an ergogenic effect associated with this mechanism.
It is possible that the greater benefit associated with SP2 loading on exercise performance demonstrated here may be a result of improved physical function (as described herein), which may have occurred as a result of mechanisms induced by SP1 in the body being maintained and then enhanced by further SP supplementation. This improvement may also be related to the washout period used, particularly when the SP2 trial followed SP1. As noted earlier, a 14-day washout period may not have been long enough to eliminate the effects of SP1, with these effects possibly being augmented by the second phase of SP loading, resulting in an additive effect and improved exercise performance, as demonstrated by Czuba et al. (2009) . Of further interest is whether a single larger (fixed) dose of SP (i.e., 4 g/day as used in the studies by Kreider et al., 1992, and Folland et al., 2008) could improve 1,000-kJ time-trial performance and whether a second phase of this larger dose would impart any further exercise benefits (i.e., an additive effect). If an additive effect occurred, then further studies would be needed to determine the exact time period between the first and second phases of SP loading that resulted in optimal exercise performance.
In conclusion, the current study demonstrated that an initial load of SP improved aerobic capacity in trained cyclists, while subsequent loading resulted in further greater mean VO 2peak values, as well as greater mean power during the early stages of a 1,000-kJ time trial. These results suggest that a second supplementation period of SP should be performed before cyclists compete in time-trial events or that the initial SP dose should be larger than the 50 mg · kg FFM -1 · day -1 used here. Further studies are needed to investigate these issues.
